23-NHL-29-DO: MK2140-003, A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

Grants and Contracts Details

StatusActive
Effective start/end date6/26/23 → 6/26/25

Funding

  • Merck Sharp & Dohme Corporation: $22,287.00